

REMARKS

The Office, in the Office Communication mailed on August 16, 2006, objected to the specification for failing to include, in the Figures, sequence identifiers for the sequences disclosed in Figures 2A-2C, Figures 5A-5C, Figures 21A-21B, and Figure 25 or in the description of the drawings on pages 29-40 of the specification. The specification, in the description of the drawings, has been amended to identify each nucleic acid or amino acid sequence using a unique sequence identifier. Applicants submit that the present amendment overcomes the objection to the specification and to the drawings.


In addition, a typographical error has been corrected in the paragraph beginning at page 31, line 23, of the specification, and new claims 25 and 26 have been added. New claim 25 finds support, for example, at page 17, lines 15-24, of the specification as filed, and new claim 26 finds support, for example, at page 15, lines 16-24, and page 18, line 25, to page 19, line 6, of the specification as filed.

No new matter has been added by the present amendments.

If there are any additional charges or any credits, please apply them to
Deposit Account No. 03-2095.

Respectfully submitted,

Date: 22 September 2006



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045